|
Papillary thyroid carcinoma
|
0.900 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Papillary thyroid carcinoma
|
0.900 |
Biomarker
|
disease |
MGD |
|
|
|
|
Papillary thyroid carcinoma
|
0.900 |
SomaticCausalMutation
|
disease |
ORPHANET |
Moreover, there was no overlap between PTC with RET/PTC, BRAF, or RAS mutations, which altogether were present in 66% of cases.
|
12670889 |
2003 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
PTC with RET/PTC rearrangement as well as the TPC-1 cell line (the only one harboring RET/PTC rearrangement) did not show the BRAF(V599E) mutation.
|
12881714 |
2003 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that BRAF mutations may play a critical role in the carcinogenesis of papillary carcinoma of the thyroid.
|
14508525 |
2003 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Activating point mutations of the BRAF gene have been recently reported in papillary thyroid carcinomas.
|
14602780 |
2003 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutation occurred in PTC at a significantly higher frequency in male patients than in female patients.
|
12907632 |
2003 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that activating BRAF mutations may be an important event in the development of papillary thyroid cancer.
|
12697856 |
2003 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
BRAF(V599E) mutations were unique to PTCs, and not found in any of the other types of differentiated follicular neoplasms arising from the same cell type (0 of 46).
|
12670889 |
2003 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Examination of 126 patients with papillary thyroid cancer showed that BRAF mutation correlated significantly with distant metastasis (P = 0.033) and clinical stage (P = 0.049).
|
12970315 |
2003 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
The analysis of exons 11 and 15 of BRAF gene revealed the T1796A (V599E) mutation in 32% of cases, and this alteration is significantly associated with PTC tall cell variant.
|
15273715 |
2004 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Overall, BRAF(V599E) mutation was found in 18/56 (32.1%) PTCs.
|
15272920 |
2004 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
In FNA samples grouped according to the preoperative cytologic findings (malignant, n = 25; benign, n = 11; and indeterminate, n = 55), a BRAF mutation confirmed the diagnosis of PTC in 72% of carcinomas within the malignant group, and it established the diagnosis of PTC in 16% of carcinomas within the indeterminate group.
|
15102681 |
2004 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Thus, we have demonstrated the usefulness of BRAF mutation detection on FNAB specimens that can help diagnose and identify those PTC patients who may need more aggressive surgical treatment and vigilant clinical monitoring.
|
15181070 |
2004 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
The differences in the prevalence of BRAF(T1796A) mutations between childhood and adult cases of PTC may well reflect inherent differences in the clinical features of these cancers between the two age groups.
|
15356022 |
2004 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas.
|
15095090 |
2004 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
These results indicate that BRAF mutation and RET/PTC rearrangements are molecular markers of PTC that can be applied to FNA in adjunct to traditional cytology.
|
15472223 |
2004 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
This study has confirmed the high prevalence of BRAF(V599E) in PTC and has shown that the mutation is almost exclusively seen in PTC with a papillary or mixed follicular-papillary growth pattern, regardless of the cytological features of the neoplastic cells.
|
14743508 |
2004 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
A genetico-clinical association analysis showed a statistically significant correlation between BRAF mutation and development of PTCs of the classic papillary histotype (P = 0.038).
|
15126572 |
2004 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
We conclude that the frequency of BRAF mutations is significantly lower (P = 0.0008) in post-Chernobyl PTC than in adult sporadic PTC, whereas no significant difference was found between post-Chernobyl and sporadic childhood PTCs.
|
15356020 |
2004 |
|
Papillary thyroid carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
A high prevalence of activating mutation of the B type Raf kinase (BRAF) gene was recently reported in papillary thyroid cancer (PTC).
|
15001635 |
2004 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population.
|
15515191 |
2004 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Point mutations of the BRAF gene have been recently described with high prevalence in papillary thyroid carcinomas.
|
15145515 |
2004 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Like the previously reported mutually exclusive relationship between BRAF mutation and other Ras pathway components such as RET/PTC rearrangement, a mutually exclusive relationship also exists between BRAF mutation and RASSF1A methylation in thyroid tumorigenesis.
|
14996725 |
2004 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Moreover, mutations in the BRAF gene have recently been suggested as an alternate predominant cause of colorectal and papillary thyroid cancers without ras mutations.
|
15186612 |
2004 |